Company / Operating Cash Flow per Share
Alaunos Therapeutics, Inc. Operating Cash Flow per Share History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$3.10
FY2025
5-year range
-$18.82 / -$0.27
FY2021-FY2025
Trend
+83.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share returned to growth in FY2025 after 3 years of decline, reaching $-3.10.
Based on SEC 10-K filings.
-3.10 in FY2025.
Declined from $-1.82 to $-3.10 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 83.5% year-over-year.
- Peak operating cash flow per share was recorded in FY2021.
- Lowest operating cash flow per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.10 | +83.5% |
| FY2024 | -$18.82 | -932.1% |
| FY2023 | -$1.82 | -541.3% |
| FY2022 | -$0.28 | -7.0% |
| FY2021 | -$0.27 | +2.3% |
| FY2020 | -$0.27 | +19.9% |
| FY2019 | -$0.34 | +17.0% |
| FY2018 | -$0.41 | +12.4% |
| FY2013 | -$0.47 | -64.0% |
| FY2012 | -$0.28 | -12.2% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026